New heart valve offers hope for High-Risk chinese patients
NCT ID NCT03466918
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new heart valve, the SAPIEN 3, in 58 Chinese patients with severe aortic stenosis who were at high risk for traditional open-heart surgery. The valve was implanted using a thin tube through a blood vessel, avoiding the need for open surgery. The main goal was to see how many patients survived and how safe the procedure was.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAPIEN 3 transcatheter heart valve
What this could lead to
If successful, this could provide a less invasive treatment option for Chinese patients with severe aortic stenosis who are too high-risk for open-heart surgery.
What could go wrong
This was a small, single-arm study (58 participants) with no comparison group, so results may not apply broadly. Risks include stroke, bleeding, or valve-related complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fuwai Hospital, CAMS&PUMC
Beijing, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
WestChina Hospital, Sichuan University
Chengdu, China
-
Zhongshan Hospital Fudan University
Shanghai, China